Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
- PMID: 38606900
- PMCID: PMC11470109
- DOI: 10.1177/29767342241245095
Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
Abstract
Many patients who receive treatment for opioid use disorder (OUD) report experiencing chronic pain (CP), which is associated with high levels of ongoing nonmedical opioid use and low retention in OUD treatment. In pilot studies of patients with OUD receiving buprenorphine or methadone who had CP, cognitive behavioral therapy (CBT) attenuated nonmedical opioid use compared with treatment-as-usual (TAU), but patients in both treatment arms exhibited similar pain improvements. Adding exercise and stress reduction to this model may augment pain-related outcomes. With funding from National Institutes of Health, we plan to conduct a randomized clinical trial of 316 patients with OUD and CP to test the effectiveness of TAU compared with Stepped Care for Patients to Optimize Whole Recovery (SC-POWR) to reduce nonmedical opioid use and pain (primary outcomes) (Aim 1) and decrease pain intensity and interference, alcohol use, anxiety, depression and stress, and improve sleep (secondary outcomes) (Aim 2). Eligible participants will be randomized to receive TAU (buprenorphine or methadone and at least once a month individual or group counseling) or SC-POWR (ie, TAU and up to 12 CBT sessions) for 24 weeks. Based on prespecified nonresponse criteria, SC-POWR may be stepped up at week 6 to receive onsite weekly group sessions of exercise (Wii Fit, Tai Chi) and "stepped up" again at week 15 to receive weekly group sessions of stress reduction (relaxation training, auricular acupuncture). They will be followed for another 24 weeks to evaluate durability of treatment response for illicit opioid use, alcohol use, pain, anxiety, depression, stress, sleep, and retention in medications for OUD (Aim 3).
Keywords: buprenorphine; cognitive behavioral therapy; effectiveness; exercise; methadone; opioid-related disorders; pain; randomized clinical trial; stepped care; stress.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain.Drug Alcohol Depend. 2019 Jan 1;194:460-467. doi: 10.1016/j.drugalcdep.2018.10.015. Epub 2018 Nov 13. Drug Alcohol Depend. 2019. PMID: 30508769 Free PMC article. Clinical Trial.
-
Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.Drug Alcohol Depend. 2021 Apr 1;221:108619. doi: 10.1016/j.drugalcdep.2021.108619. Epub 2021 Feb 15. Drug Alcohol Depend. 2021. PMID: 33667781 Free PMC article.
-
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.Addict Sci Clin Pract. 2022 Sep 4;17(1):47. doi: 10.1186/s13722-022-00326-1. Addict Sci Clin Pract. 2022. PMID: 36057608 Free PMC article.
-
Medications for management of opioid use disorder.Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105. Am J Health Syst Pharm. 2019. PMID: 31361869 Review.
-
Systematic review on the clinical management of chronic pain and comorbid opioid use disorder.Adicciones. 2023 Jul 1;35(2):197-212. doi: 10.20882/adicciones.1680. Adicciones. 2023. PMID: 35472158 English, Spanish.
Cited by
-
Dopaminergic Homeostatic Therapy (DHT™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS®) Screening.Acta Sci Neurol. 2025 Apr 30;8(5):70-88. Acta Sci Neurol. 2025. PMID: 40896766 Free PMC article.
-
Recent advances in the treatment of chronic pain and substance use disorders.Curr Opin Psychol. 2025 Apr;62:101977. doi: 10.1016/j.copsyc.2024.101977. Epub 2024 Dec 13. Curr Opin Psychol. 2025. PMID: 39705790 Review.
References
-
- Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289(18):2370–2378. - PubMed
-
- Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. J. Pain Symptom Manage. 2000;19(1):53–62. - PubMed
-
- Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005;113(3):340–346. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous